Drug Trial Radar · NCT04483375
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jul 24, 2020
Primary completion
Nov 17, 2020
Study completion Nov 17, 2020
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
Conditions
- Coronavirus Disease 2019(COVID-19)
Interventions
SCTA01Biological
recombinant humanized anti-SARS-CoV-2 monoclonal antibody
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: 7 days
- Maximal Tolerable Dose(MTD)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing SHIJITAN Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.